Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
27 févr. 2024 07h58 HE
|
Clearmind Medicine Inc.
New patent applications build upon Clearmind’s broad IP protection in the psychedelic space Vancouver, Canada, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE:...
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
23 févr. 2024 07h06 HE
|
Clearmind Medicine Inc.
For the first time, patients with alcohol use disorder will receive the company's unique and proprietary psychedelic - MEAI Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine...
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
20 févr. 2024 07h14 HE
|
Clearmind Medicine Inc.
Vancouver, Canada, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of...
Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
05 févr. 2024 07h51 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery...
Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
01 févr. 2024 08h15 HE
|
Clearmind Medicine Inc.
The licensing agreement refers to the company's dedicated treatment for cocaine addiction which previously indicated a significant decrease in cocaine craving Tel Aviv, Israel / Vancouver,...
Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
16 janv. 2024 11h19 HE
|
Clearmind Medicine Inc.
TEL AVIV, ISRAEL / VANCOUVER, CANADA, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (the “Company”), a biotech company focused on discovery and development of novel...
Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement
11 janv. 2024 09h28 HE
|
Clearmind Medicine Inc.
TEL AVIV, ISRAEL / VANCOUVER, CANADA, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (the “Company”), a biotech company focused on discovery and development of novel...
Clearmind Medicine Completed Type A Meeting with the FDA
10 janv. 2024 07h18 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...
Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments
04 janv. 2024 07h18 HE
|
Clearmind Medicine Inc.
The collaboration included filing six different US patent applications with the United States Patent and Trademark Office to protect novel combinations of psychedelics with SciSparc's PEA Tel Aviv,...
Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards
14 déc. 2023 08h26 HE
|
Clearmind Medicine Inc.
Nasdaq Has Informed the Company That a Bid Price Deficiency of its Common Shares Has Been CuredTel Aviv, Israel / Vancouver, Canada, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc....